VEGFA and cancer: The fact that VEGF levels correlated with cancer staging and prognosis, has supported the idea of using anti-VEGF strategies, such as anti VEGF antibodies (e.g. bevacizumab) or inhibitors of the VEGF receptors in combination with chemotherapy or alone to improve survival of patients with metastatic NSCLC [103,108].